Supernus Pharmaceuticals, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for SUPN, updated each market day.
SUPN AI Sentiment
AI sees no strong directional signal for Supernus Pharmaceuticals, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Sector
Exchange
Market Cap
$2,965,458,168
Cap Tier
Employees
778
Headquarters
ROCKVILLE, MD
Listed Since
May 1, 2012
Website
SUPN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SUPN Volatility
Supernus Pharmaceuticals, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
